Research

A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease

Nicholas S Hopkinson¹ , Rachel C Tennant² , Mark J Dayer¹ , Elisabeth B Swallow¹ , Trevor T Hansel² , John Moxham³ and Michael I Polkey¹

¹  Respiratory Muscle Laboratory, Royal Brompton Hospital, Fulham Rd, London SW3 6NP, UK

²  Clinical Studies Unit National Heart and Lung Institute, Royal Brompton Hospital, Fulham Rd, London SW3 6NP, UK

³  Respiratory Muscle Laboratory, Guy's King's and St Thomas' School of Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, UK

author email corresponding author email

Respiratory Research 2007, 8:25doi:10.1186/1465-9921-8-25

Published:	13 March 2007

Abstract

Background

Skeletal muscle depletion is an important complication of chronic obstructive pulmonary disease (COPD) but little prospective data exists about the rate at which it occurs and the factors that promote its development. We therefore prospectively investigated the impact of disease severity, exacerbation frequency and treatment with corticosteroids on change in body composition and maximum isometric quadriceps strength (QMVC) over one year.

Methods

64 patients with stable COPD (FEV₁ mean (SD) 35.8(18.4) %predicted) were recruited from clinic and studied on two occasions one year apart. Fat free mass was determined using bioelectrical impedance analysis and a disease specific regression equation.

Results

QMVC fell from 34.8(1.5) kg to 33.3(1.5) kg (p = 0.04). The decline in quadriceps strength was greatest in those with the highest strength at baseline (R -0.28 p = 0.02) and was not correlated with lung function, exacerbation frequency or steroid treatment. Decline in fat free mass was similarly higher in those with largest FFM at baseline (R = -0.31 p = 0.01) but was more strongly correlated with greater gas trapping (R = -0.4 p = 0.001). Patients with frequent exacerbations (>1 per year) (n = 36) experienced a greater decline in fat free mass compared to infrequent exacerbators (n = 28) -1.3(3.7)kg vs. +1.2(3.1)kg (p = 0.005), as did patients on maintenance oral steroids (n = 8) -2.8(3.3) kg vs. +0.2(3.5) kg (p = 0.024) whereas in those who stopped smoking (n = 7) fat free mass increased; +2.7(3.1) kg vs. -0.51(3.5) kg (p = 0.026).

Conclusion

Decline in fat free mass in COPD is associated with worse lung function, continued cigarette consumption and frequent exacerbations. Factors predicting progression of quadriceps weakness could not be identified from the present cohort.